Hims & Hers Health (HIMS) 2026 Evercore Global TMT Conference summary
Event summary combining transcript, slides, and related documents.
2026 Evercore Global TMT Conference summary
2 Jun, 2026Strategic vision and growth targets
Aims to transform healthcare by leveraging a closed-loop ecosystem, expanding specialties, and pursuing international growth.
Set ambitious 2030 targets: $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, driven by global expansion, specialty broadening, and partnerships.
Recent acquisition of Eucalyptus, with a $450 million run-rate and triple-digit growth, accelerates global reach and cultural alignment.
Focused on integrating recent acquisitions and scaling international operations, especially in Australia, Canada, the U.K., and Germany.
Investment priorities include technology, AI, and consumer experience, aiming for market leadership in each specialty.
Operational execution and investment cycle
Investments are aimed at long-term yield, prioritizing market leadership and positive free cash flow.
International operations expected to run at break-even near term, with future profit generation as scale is achieved.
Technology and AI investments have enabled rapid specialty launches and improved platform efficiency.
Capital allocation prioritizes durable growth, with flexibility for shareholder returns via buybacks when appropriate.
M&A remains opportunistic but highly strategic, with current focus on integrating and maximizing value from recent deals.
Competitive advantages and platform differentiation
Competitive moat built on infrastructure, scale, global reach, provider network, and brand trust.
Rich dataset and technology talent enable personalized care and continuous platform improvement.
Platform approach allows consumers to engage across multiple specialties, deepening retention and data insights.
AI is used to drive cost efficiencies, enhance consumer experience, and support new product development.
Brand trust and operational excellence are key differentiators in a rapidly evolving, AI-driven market.
Latest events from Hims & Hers Health
- Q2 2026 revenue up 38–40% to $753M, but net loss $86M amid global expansion and higher costs.HIMS
Q2 2026 - Directors, auditor, and executive compensation were approved; Q&A to be answered post-meeting.HIMS
AGM 2026 - Rapidly scaling personalized health platform targets $6.5B+ revenue by 2030.HIMS
Investor presentation - Q1 2026 revenue rose 4% to $608M, but net loss widened on restructuring and margin pressure.HIMS
Q1 2026 - Proxy covers director elections, auditor ratification, and executive pay, highlighting strong growth and governance.HIMS
Proxy filing - Votes sought for nine directors, auditor ratification, and executive pay at June 2026 meeting.HIMS
Proxy filing - 2025 revenue up 59% to $2.35B, with strong subscriber and specialty growth, and robust 2026 outlook.HIMS
Q4 2025 - Q2 revenue up 52% to $315.6M, net income $13.3M, 1.9M subscribers, and raised full-year guidance.HIMS
Q2 2024 - 2024 revenue up 69% to $1.5B, net income $126M, 2025 guidance set at $2.3–$2.4B revenue.HIMS
Q4 2024